263 related articles for article (PubMed ID: 16524698)
21. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients.
Centorrino F; Baldessarini RJ; Kando JC; Frankenburg FR; Volpicelli SA; Flood JG
J Clin Psychopharmacol; 1994 Apr; 14(2):119-25. PubMed ID: 8195452
[TBL] [Abstract][Full Text] [Related]
22. Unanticipated plasma concentrations in two clozapine-treated patients.
Alfaro CL; McClure RK; Vertrees JE; Benavides R
Ann Pharmacother; 2001 Sep; 35(9):1028-31. PubMed ID: 11573850
[TBL] [Abstract][Full Text] [Related]
23. Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients.
González-Esquivel DF; Castro N; Ramírez-Bermúdez J; Custodio V; Rojas-Tomé S; Castro-Román R; Jung-Cook H
Arzneimittelforschung; 2011; 61(6):335-9. PubMed ID: 21827043
[TBL] [Abstract][Full Text] [Related]
24. Association of clozapine and norclozapine levels with patient and therapy characteristics-focus on interaction with valproic acid.
Panić B; Jovanović M; Lukić V; Vučićević K; Miljković B; Milovanović S
Eur J Clin Pharmacol; 2023 Nov; 79(11):1557-1564. PubMed ID: 37733278
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic drug monitoring of clozapine and relapse--a retrospective study of routine clinical data.
Ulrich S; Baumann B; Wolf R; Lehmann D; Peters B; Bogerts B; Meyer FP
Int J Clin Pharmacol Ther; 2003 Jan; 41(1):3-13. PubMed ID: 12564740
[TBL] [Abstract][Full Text] [Related]
26. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions.
Tan MSA; Honarparvar F; Falconer JR; Parekh HS; Pandey P; Siskind DJ
Psychopharmacology (Berl); 2021 Mar; 238(3):615-637. PubMed ID: 33410989
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic drug monitoring of clozapine and norclozapine in human serum using ultra-performance liquid chromatography- tandem mass spectrometry.
Ming DS; Heathcote J
J Anal Toxicol; 2009 May; 33(4):198-203. PubMed ID: 19470221
[TBL] [Abstract][Full Text] [Related]
28. Clozapine-associated development of second-onset obsessive compulsive symptoms in schizophrenia: impact of clozapine serum levels and fluvoxamine add-on.
Gahr M; Rehbaum K; Connemann BJ
Pharmacopsychiatry; 2014 May; 47(3):118-20. PubMed ID: 24846087
[TBL] [Abstract][Full Text] [Related]
29. A machine learning approach using auditory odd-ball responses to investigate the effect of Clozapine therapy.
Ravan M; Hasey G; Reilly JP; MacCrimmon D; Khodayari-Rostamabad A
Clin Neurophysiol; 2015 Apr; 126(4):721-30. PubMed ID: 25213349
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations.
Llorca PM; Lancon C; Disdier B; Farisse J; Sapin C; Auquier P
J Psychiatry Neurosci; 2002 Jan; 27(1):30-7. PubMed ID: 11836974
[TBL] [Abstract][Full Text] [Related]
31. Neuroleptic-resistant schizophrenic patients treated by clozapine: clinical evolution, plasma and red blood cell clozapine and desmethylclozapine levels.
Aymard N; Baldacci C; Leyris A; Smagghe PO; Tribolet S; Vacheron MN; Viala A; Caroli F
Therapie; 1997; 52(3):227-32. PubMed ID: 9366107
[TBL] [Abstract][Full Text] [Related]
32. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients.
Liu HC; Chang WH; Wei FC; Lin SK; Lin SK; Jann MW
Ther Drug Monit; 1996 Apr; 18(2):200-7. PubMed ID: 8721285
[TBL] [Abstract][Full Text] [Related]
33. Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics.
Tóth K; Csukly G; Sirok D; Belic A; Kiss Á; Háfra E; Déri M; Menus Á; Bitter I; Monostory K
Int J Neuropsychopharmacol; 2017 Jul; 20(7):529-537. PubMed ID: 28340122
[TBL] [Abstract][Full Text] [Related]
34. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
[TBL] [Abstract][Full Text] [Related]
35. Lower levels of whole blood serotonin in obsessive-compulsive disorder and in schizophrenia with obsessive-compulsive symptoms.
Ma N; Tan LW; Wang Q; Li ZX; Li LJ
Psychiatry Res; 2007 Feb; 150(1):61-9. PubMed ID: 17291595
[TBL] [Abstract][Full Text] [Related]
36. Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo.
Lane HY; Chiu CC; Kazmi Y; Desai H; Lam YW; Jann MW; Chang WH
Drug Metabol Drug Interact; 2001; 18(3-4):263-78. PubMed ID: 11791889
[TBL] [Abstract][Full Text] [Related]
37. Serum level of clozapine and relapse.
Ulrich S; Wolf R; Staedt J
Ther Drug Monit; 2003 Apr; 25(2):252-5. PubMed ID: 12657924
[TBL] [Abstract][Full Text] [Related]
38. The usefulness of monitored therapy using Clozapine concentration in the blood serum for determining drug dose in Polish schizophrenic patients.
Piwowarska J; Radziwoń-Zaleska M; Dmochowska M; Szepietowska E; Matsumoto H; Sygitowicz G; Pilc A; Łukaszkiewicz J
Pharmacol Rep; 2016 Dec; 68(6):1120-1125. PubMed ID: 27588387
[TBL] [Abstract][Full Text] [Related]
39. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy.
Costa-Dookhan KA; Agarwal SM; Chintoh A; Tran VN; Stogios N; Ebdrup BH; Sockalingam S; Rajji TK; Remington GJ; Siskind D; Hahn MK
Expert Opin Drug Saf; 2020 Jan; 19(1):43-57. PubMed ID: 31770500
[No Abstract] [Full Text] [Related]
40. Intra-individual variation of clozapine and norclozapine plasma levels in clinical practice.
Turrion MC; Perez J; Bernardo M; Fernandez-Egea E
Rev Psiquiatr Salud Ment (Engl Ed); 2020; 13(1):31-35. PubMed ID: 31122757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
